Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708924 | 0.92 | KDM4E (0.34) | CA12CA1CA7CA9CA13 | |
| SCHEMBL3705699 | 0.92 | KDM4E (0.34) | CA12CA1CA7CA9CA13 | |
| SCHEMBL9898796 | 0.90 | KDM4E (0.31) | KDM4EMEN1ALDH1A1LMNACYP2C9 | |
| SCHEMBL25844438 | 0.90 | CA12 (0.31) | CA12CA1CA7CA9CA13 | |
| SCHEMBL1010971 | 0.90 | CA12 (0.31) | CA12CA1CA7CA9CA13 | |
| SCHEMBL3698200 | 0.89 | CA12 (0.33) | CA12CA1CA7CA9CA13 | |
| SCHEMBL30708909 | 0.89 | CA12 (0.33) | CA12CA1CA7CA9CA13 | |
| SCHEMBL25844473 | 0.89 | MDM2 (0.32) | CA12CA1CA7CA9CA13 | |
| SCHEMBL1009516 | 0.88 | PGR (0.32) | CA12CA1CA7CA9CA13 | |
| SCHEMBL29664129 | 0.88 | PGR (0.32) | CA12CA1CA7CA9CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9465234-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150301357-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2494408-B9 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9097916-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2494408-B1 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20140225049-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8741188-B2 | Ophthalmic devices comprising photochromic materials having extended pi-conjugated systems | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8518305-B2 | Photochromic materials | TRANSITIONS OPTICAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130065056-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | JOHNSON & JOHNSON VISION CARE, INC. | 2013-03-14 | — | — | US | disclosed |
| US-8388872-B2 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110108781-A1 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110042629-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-1872173-B9 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1872173-B1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090072206-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1869140-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | Johnson and Johnson Vision Care, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110513-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060226402-A1 | Ophthalmic devices comprising photochromic materials having extended PI-conjugated systems | KIM BEON-KYU | 2006-10-12 | — | — | US | disclosed |
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | TRANSITIONS OPTICAL, INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060228557-A1 | Photochromic materials having extended pi-conjugated systems and compositions and articles including the same | INCENP, PCNA, INTS6 | CA12 1603/4885CA1 3180/4885CA7 2105/4885 |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | INTS6, INCENP, PCNA | CA12 1620/4885CA1 3324/4885CA7 1967/4885 |
| US-20110108781-A1 | PHOTOCHROMIC MATERIALS | INCENP, SMCHD1, NEDD8 | CA12 525/4885CA1 867/4885CA7 895/4885 |
| US-20130065056-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | INCENP, INTS6, IPO4 | CA12 1680/4885CA1 3474/4885CA7 1155/4885 |
| US-20110042629-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | IPO4, INCENP, IPO11 | CA12 1788/4885CA1 3573/4885CA7 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.